What risks come with PT-141?

What risks matter before you consider the benefits?

The desire drug PT-141 works through changes within the brain. This page explains unwanted effects and who faces added risks. Approval includes women still before menopause, distressed by low desire that came after a time when desire was normal. That loss isn't tied to one partner or a particular setting, and the approval doesn't include a man's use, use after menopause, or better performance.

I'd check the blood pressure warning before weighing a promised benefit. If high blood pressure isn't under control, the label rules out use because the medicine may briefly make the pressure higher; known heart or blood vessel disease rules out use too. People who are pregnant or breastfeeding don't have established safety to rely on. Sickness, liver harm, skin darkening, and unchecked powders add concerns.

Some people describe more desire and pleasure, but others get no help. You can't judge safety from the happier accounts. Your health and the study findings matter when you weigh those reports.

What do people describe outside the studies?

People describe these experiences after using PT-141 for research purposes, away from formal trials. No study has checked these experiences against a placebo, a treatment without the tested medicine. “Often” describes how often an account appears, not your chance of feeling the same effect.

Wanting sex and enjoying it. Very often, people describe wanting sex more, before any bodily change. Accounts often describe a body more ready for sex and more sensitive to touch. People also often describe orgasms that come more easily or feel stronger; an orgasm is the high point of pleasure during sex.

Erections and waiting. Men often report erections they hadn't planned, despite having no approved use. Effects often take time to begin and then last a long time. People differ on whether that helps, so you can't assume the timing will suit you.

Closeness with a partner. Some people describe feeling closer emotionally to a partner. These accounts appear now and then, less often than increased desire. Your relationship can't be judged from another person's account of closeness.

Sickness and discomfort. Accounts of feeling sick are very common, sometimes making people stop. Heat or flushing, headaches, and sore skin near the shot come up often. Reports also mention tingling, pins-and-needles, odd skin feelings, tiredness, and sleepiness now and then.

Changes that last, or no help at all. Some people describe darker gums or skin with frequent use, and freckles or moles changing color. Some people say the color didn't return to normal. Others describe no benefit at all, sometimes with sickness as their only change.

Which health problems could make the risks greater?

Your health can change what these warnings mean for you. Studies and the medicine's label describe some known harms. If you're pregnant or breastfeeding, missing safety tests leave risks unknown.

Who falls within approval? Women before menopause qualify only when low desire causes distress and wasn't lifelong. Low desire isn't tied to a particular partner or kind of sexual contact. PT-141 isn't approved to treat men or women beyond menopause, or to improve performance. ^{[7] [16] [3]}

Blood pressure can rise. PT-141 may cause a short rise, along with a slightly slower pulse. The label excludes treatment if you have high blood pressure that remains uncontrolled. Treatment is also excluded when heart disease or disease in blood vessels is known; blood pressure checks and early safety tests support this warning. ^{[7] [17] [18]}

Sickness can make people stop. Long-term studies found sickness in nearly forty percent; some people vomited too. Sickness was a known reason for leaving the studies. You can't weigh the gains fairly without that cost. ^{[4] [19] [3]}

Darkening can last. Freckles and moles may change color with frequent use, as can your face, breasts, and gums. People with darker skin already face more risk. The label doesn't promise that the color will fully return to normal. ^[7]

Liver risks need attention. The LiverTox medical review found mild liver changes in blood tests. Clear harm to the liver has also been reported in rare cases. Rare doesn't mean you can rule that harm out. ^[10]

Unchecked powders bring added doubt. Lab tests confirmed related drugs were present in products from the black market, without medicine quality checks. You can't be sure of the drug, strength, or purity. Serious harm after a shot was reported with a related drug, rather than in a trial of this medicine. ^{[20] [21]}

Eating and body weight can change. The brain cells this drug acts on also govern hunger. In studies with frequent shots, women ate less, and their weight fell. That doesn't give you an approved treatment for losing weight. ^{[22] [23]}

Pregnancy and breastfeeding leave unanswered questions. Human studies haven't established that use is safe for pregnant or breastfeeding people. Missing tests aren't proof that harm happened. But missing tests can't give you reassurance that the drug is safe.

Why did researchers turn from tanning to desire?

PT-141 came from melanotan-II, a drug first studied for tanning. Once sexual effects drew attention, tests using the nose studied men troubled by poor erections and women facing sexual problems. Later research focused on a shot for women, so the original aim changed.

The FDA approval in June 2019 concerned bremelanotide for women still before menopause and distressed by lost desire. Those women used to have normal desire; desire stayed low in different sexual settings, rather than just with one partner. That history explains the interest, but doesn't extend approval to your own situation. A man's concerns may be quite different. ^{[24] [25] [16] [3] [7] [26] [1]}